Navigation Links
Wasserman Morris Initiates Research Coverage on Crdentia
Date:3/11/2008

Rated Speculative Buy, $0.51 Price Target

DALLAS, March 11 /PRNewswire-FirstCall/ -- Crdentia Corp. (OTC Bulletin Board: CRDT), a leading healthcare staffing company, today announced that Wasserman Morris & Company, an independent investment research firm, initiated coverage on the Company with a 'Speculative Buy' rating and a price target of $0.51 per share. The report is available at http://www.crdentia.com/corporate/about/investor/ and through http://www.wassermanmorris.com.

About Crdentia Corp.

Crdentia Corp., one of the nation's leading providers of healthcare staffing solutions, is focused on recruiting talented national and international healthcare professionals to meet the ever-increasing employment needs of over 2,300 clients. Crdentia is one of the few companies that can provide quality temporary staff for all healthcare industry positions including local nurses, travel nurses, allied health, locum tenens and home care professionals. For more information, visit http://www.crdentia.com.

Forward Looking Statements

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, a limited operating history with no earnings; reliance on the Company's management team, members of which have other business interests; the ability to successfully implement the Company's business plan; the ability to continue as a going concern; the ability to fund the Company's business and acquisition strategy; the growth of the temporary healthcare professional staffing business; difficulty in managing operations of acquired businesses; uncertainty in government regulation of the healthcare industry; and the limited public market for the Company's common stock. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. Crdentia undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Crdentia Corp.

John Kaiser, CEO

Phone: 972.850.0780

Fax: 972.392.2722

jkaiser@crdentia.com

Jim TerBeest, CFO

Phone: 972.850.0780

Fax: 972.392.2722

jterbeest@crdentia.com


'/>"/>
SOURCE Crdentia Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bond Laboratories Selects Wasserman Media Group
2. Pain Management For Your Pets, Key Information Every Pet Owner Should Know - Live Webcast to Pet Owners, March 13, 8:00 p.m. to 9:00 p.m. (EDT) Via Morris Animal Foundation
3. Pain Management For Pets, Key Strategies For Veterinarians - Live Webcast to Veterinarians, March 13, 7:00 p.m. to 8:00 p.m. (EDT) Via Morris Animal Foundation
4. Chicago Tribune Does Story on Canine Cancer, Morris Animal Foundation (MAF) Effort to Find a Cure - MAF Can Provide Information - Local Angles for a Feature Story
5. The Blue Buffalo Foundation for Cancer Research Sponsors Six Morris Animal Foundation Cancer Studies
6. Philip Morris International Spin-off Should Spur Nations to Take Urgent Action to Reduce Tobacco Use
7. Perfect Holiday Gift Idea for the Pet-Animal Lover - Pet Health Manual Available With Donation to Morris Animal Foundation
8. PetScreen Supports Morris Animal Foundation Canine Cancer Campaign; Co-Sponsors Two Canine Cancer Studies
9. Morrison Takes Aim at Underage Drinking in New Radio Campaign
10. Morris Animal Foundation Featured on NASCAR Racecar to Raise Awareness of Pet Cancer
11. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
Breaking Medicine Technology: